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Abstract
Background: Pain (physical discomfort) and challenging behaviour are highly prevalent in nursing home residents
with dementia: at any given time 45-80% of nursing home residents are in pain and up to 80% have challenging
behaviour. In the USA Christine Kovach developed the serial trial intervention (STI) and established that this
protocol leads to less discomfort and fewer behavioural symptoms in moderate to severe dementia patients. The
present study will provide insight into the effects of implementation of the Dutch version of the STI-protocol (STA
OP!) in comparison with a control intervention, not only on behavioural symptoms, but also on pain, depression,
and quality of life. This article outlines the study protocol.
Methods/Design: The study is a cluster randomized controlled trial in 168 older people (aged >65 years) with
mild or moderate dementia living in nursing homes. The clusters, Dutch nursing homes, are randomly assigned to
either the intervention condition (training and implementation of the STA OP!-protocol) or the control condition
(general training focusing on challenging behaviour and pain, but without the step-wise approach). Measurements
take place at baseline, after 3 months (end of the STA OP! training period) and after 6 months.
Primary outcome measures are symptoms of challenging behaviour (measured with the Cohen-Mansfield Agitation
Inventory (CMAI) and the Neuropsychiatric Inventory-Nursing Home version (NPI-NH)), and pain (measure with the
Dutch version of the Pain Assessment Checklist for Seniors (PACSLAC-D) and the Minimum Data Set of the
Resident Assessment Instrument (MDS-RAI) pain scale). Secondary outcome measures include symptoms of
depression (Cornell and MDS-RAI depression scale), Quality of Live (Qualidem), changes in prescriptions of
analgesics and psychotropic drugs, and the use of non-pharmacological comfort interventions (e.g. snoezelen,
reminiscence therapy).
Discussion: The transfer from the American design to the Dutch design involved several changes due to the
different organisation of healthcare systems. Specific strengths and limitations of the study are discussed.
Trial registration: Netherlands Trial Register (NTR): NTR1967
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The number of dementia patients in the Netherlands is
estimated to be 235,000. Due to the aging population
and the rising life expectancy, this number may exceed
500,000 in 2050. In 2000, around 30% of the people
with dementia were living in nursing homes [1,2]. In
nursing home residents, pain is highly prevalent: at any
given time, 45-80% of the residents are in pain [3-6].
The most prominent features of pain in dementia
patients are challenging behaviour, such as vocalizations
(crying, screaming), noisy breathing, facial expressions
(e.g. grimacing), restless or strained body expressions,
aggressiveness and resistance to care [7,8]. These pat-
terns of behaviour (like delusions, hallucinations, agita-
tion/aggression, dysphoria/depression, anxiety, euphoria/
elation, apathy/indifference, disinhibition, irritability/
lability, aberrant motor behaviour, night-time distur-
bances, and appetite/eating disturbances) are also
known as neuropsychiatric symptoms of dementia,
which are a prominent feature of dementia: in nursing
homes up to 80-85% of the residents have one or more
of these (clinically relevant) neuropsychiatric symptoms,
confusingly often also referred to as challenging beha-
viour [9-11].
Studies consistently show that patients with dementia
are undertreated for pain [3,12-15]. Research indicates
that both pharmacological interventions (analgesic medi-
cation) and non-pharmacological comfort measures are
underutilized [16-18]. There are many reasons for the
undertreatment of pain in this population. First, there
are difficulties in the assessment of pain and challenging
behaviour; the verbal communication of patients with
severe dementia is often limited or completely lacking,
and behavioural symptoms may provide the only indica-
tions for pain, affective discomfort or unmet needs. Sec-
ond, agitated behaviour in dementia patients may point
to pain [19], but it can also be related to affective dis-
comfort. This agitated behaviour is often treated with
psychotropic drugs (antipsychotic or anxiolytic medica-
tion) with several adverse effects, like drowsiness,
depressed mood and falls [20].
A clinical protocol, the STI - Serial Trial Intervention
(first referred to as: Assessment and treatment of Dis-
comfort in Dementia or ADD-protocol) - was developed
in the United States to address the problems in assess-
ment and management of pain and challenging beha-
viour in people with dementia [8,21-23]. It is based on
the ‘unmet need’ theoretical framework, in which beha-
viour can be seen as a way for cognitively impaired peo-
ple to express their unmet physical and affective needs
[24,25]. It is a stepped care protocol, i.e. if in one step
the assessment is negative, or if targeted interventions
fail to decrease symptoms, one moves to the next step.
The protocol is specifically designed for dementia
patients with moderate to severe cognitive impairment,
because in this particular group verbal communication
is often impaired and healthcare professionals therefore
have to rely (at least partly) on behavioural symptoms.
Since it is often unclear whether these behavioural
symptoms are a result of pain or affective discomfort, a
systematic approach for exploring and managing the
symptoms is needed.
The STI-protocol consists of five steps
The FIRST step is to perform a physical needs assess-
ment that focuses on probable causes of behavioural
symptoms related to pain or affective discomfort. The
SECOND step is to perform a needs assessment that
focuses on affective needs of people with dementia. The
THIRD step concerns a trial of non-pharmacological
comfort interventions, and the FOURTH step a trial of
analgesics. STEP FIVE refers to consultation of other
health care professionals or practitioners, or a trial of
psychotropic drugs (see Figure 1).
The effects of the protocol on patient outcomes and
professionals’ interventions have been investigated in the
USA [8,21,23]. The most recent and well-designed study
[23] used a double-blinded randomized design and
tested the effects of the protocol in subjects with moder-
ate to severe dementia. The researchers established a
significant decrease in the number of discomfort symp-
toms, measured with the Discomfort Scale - Dementia
of Alzheimer type (DS-DAT) [26]. The study however
did not assess pain with a measure developed for pain
assessment in dementia (an observational pain instru-
ment), quality of life, and depression. Another limitation
of that study was that there was insufficient blinding of
the outcome measurement.
Furthermore, it is unclear if the protocol can be effec-
tively used in other countries, with a different other
long term care (LTC) organisation. The organisation,
availability and level of education of staff and availability
of additional resources differ across settings and coun-
tries [27]. Dutch nursing homes, for instance, are differ-
ently organized than those in the USA [27,28]: a typical
Dutch nursing home accommodates 150-200 residents,
has specialized psychogeriatric wards for dementia
patients, the nurses have had a longer training than in
the USA, trained nursing home physicians (employed by
the nursing home) provide medical care, and most nur-
sing homes have also psychologists in their staff.
Therefore, in order to evaluate the STI in this setting,
some changes in the original protocol were executed. In
the original protocol for example, nurses performing the
physical examination, while in Dutch nursing homes
this is a task of a nursing home physician. For the
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introduced the expertise of the psychologist. The trans-
lated and revised version of the STI has been named
STA OP!
Research aims and hypotheses
T h ep u r p o s eo ft h i ss t u d yi st oa s s e s st h ee f f e c t so ft h e
stepped wise Dutch version of the STI (STA OP!) versus
a non-stepped wise approach to pain and behavioural
symptoms.
Research questions:
1. Does STA OP! affect the number of symptoms of
pain or challenging behaviours in nursing home resi-
dents differently (compared to usual care)?
2 .D o e st h eu s eo fS T AO P !l e a dt oac h a n g ei nu s e
of analgesics and psychotropic drugs?
3. Does the use of STA OP! result in a change in use
of non-pharmacological comfort interventions?
4 .D o e st h eu s eo fS T AO P !l e a dt oac h a n g ei n
depressive symptoms and the quality of life in
advanced dementia patients?
5. Is the effect of intervention moderated by the
Apolipoprotein Epsilon 4 (Apo-E4) status of the
patient?
It is hypothesized that implementation of the STA
OP!-protocol will lead to less pain, fewer expressions of
challenging behaviour, improved mood, higher use of
pain medication and a lower use of antipsychotics
(resulting in a decrease in side effects) with an increased
use of non-pharmacological comfort interventions.
However, we will also be able to identify findings of out-
comes that reverse the direction of the hypothesis.
Methods
Study design
The study is a cluster randomized controlled trial. The
clusters, Dutch nursing homes, are randomly assigned
to either the intervention condition (implementation of
the STA OP!-protocol) or the control condition (general
training without the step-wise approach). Measurements
take place at baseline, after 3 months (at the end of the
STA OP!-training period) and after 6 months.
The study is single blinded i.e. the researcher will
know the condition, while the research assistants per-
forming the measurements and the persons analysing
and score the video registrations are blinded. They will
also not be informed about the specific research ques-
tions and conditions.
Procedure
Recruitment
Institutions and nursing homes will be recruited within
the ‘University Network for Organisations of Elderly
Figure 1 the STI and STA OP! intervention.
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VUmc). The aim of this collaboration network is to
build greater knowledge about the best multidisciplinary
care for vulnerable elderly. The network provides an
infrastructure in which patient care/health care innova-
tions, education and research can take place. Coopera-
tion between institutions and between the institutions
and the university will lead to more knowledge and bet-
ter care. More than half of the eighteen member institu-
tions will participate in this study.
Inclusion criteria of units
The nursing homes participating in this study will be
randomized in an intervention or a control condition.
Nursing homes participating in this study have to meet
the following criteria: at least one psychogeriatric unit
willing to participate and no major organizational
changes or building activities are planned or performed
in the study period. Facilities are invited to participate
in the study, and after approval/inclusion randomized
into control or intervention.
Randomization
A separate number will be assigned in order of registra-
tion to every institution, nursing home and/or partici-
pating unit. When an institution is participating with
multiple affiliated nursing homes and/or units, we will
investigate whether there are sources of possible con-
tamination by professionals. Contamination is possible,
if a professional (e.g. nurse, physician or psychologist) is
operating in various nursing homes and/or units within
the institution. If so, these different affiliated nursing
homes and/or units will be randomized as one. In the
event that an institution with multiple affiliated nursing
homes and/or unit is participating in the study and
there is no contamination by professionals, these loca-
tions and/or units will be randomized as separate parti-
cipants. The randomization will take place by an
independent researcher using the program “Random
Allocation Software”, made available by the EMGO+
Institute for Health and Care Research in Amsterdam.
Informed consent, inclusion and exclusion criteria
Informed proxy consent will be obtained for all resi-
dents by family/caregivers. Residents will then be
screened on dementia severity, behavioural problems
and indications of pain.
Inclusion and exclusion criteria (residents) (Table 1)
Residents to be entered into the study meet the follow-
ing (ABC) pre-selection criteria:
A) Moderate to severe cognitive impairment, accord-
ing to the Global Detoriation Scale (GDS) [29].
T h o s er e s i d e n t sw i t haG D Ss c o r eo f5 ,6o r7w i l l
be eligible for this study.
B) No chronic psychiatric diagnosis other than a
dementia associated diagnosis.
The GDS score and also the absence or presence of
a chronic psychiatric score (see criteria 1 and 2), will
be assessed by the nursing home physician.
Proxy consent will be obtained for all residents meet-
ing these two criteria (A & B). However, residents who
are to be actively enrolled in the experimental or control
condition will have to meet an additional selection cri-
terion.
C) The criterion to enter the study protocol is the
amount of clinically significant symptoms of pain
and/or challenging behaviour. Inclusion criteria are:
a score of at least 44 on the Dutch version of the
Cohen-Mansfield Agitation Inventory (CMAI)
[30,31] or a score of at least 4 (frequency × severity)
on items of the Neuropsychiatric Inventory - Nur-
sing Home Version (NPI-NH) [32,33] or an indica-
tion of clinically relevant pain (intensity × frequency
≥ 2) according to the Minimum Data Set of the
Resident Assessment Instrument (MDS-RAI)-pain
scale [34] in measurement week 0 (baseline).
The following data will be gathered for all the
included residents: Pain observation (Dutch version of
the Pain Assessment Checklist for Seniors; PACSLAC-
D) [35-37] Depression (Cornell and MDS-RAI depres-
sion scale) [38,39] Quality of life (Qualidem) [40-42],
ADL (Katz) [43], co-morbidity, demographics and Apoli-
poprotein Epsilon 4 (from Buccal mucosa swabs). In
addition, 5-minutes video recordings will be made for a
blinded scoring of pain and/or discomfort.
This inclusion procedure will take place on units in
the intervention condition, as well on units in the con-
trol condition. These control units will be instructed to
treat the included residents with ‘standard care’.
’Clinical’ inclusion of residents
Those residents who initially do not score above the
threshold on the NPI-NH,M D S - R A Ip a i ns c a l eo r
the CMAI, but who have a change in behaviour after
the instrument screening, can be included in the study
(after contacting the researcher and after obtaining
proxy informed consent). Newly admitted residents on
the unit can, after a six week ‘adjustment period’, follow
the same procedure. The resident will (again) be
assessed with the same instruments as the regular resi-
dents included, after approval by the researcher. Final
analysis will be performed with and without these addi-
tional groups.
Sample size and power analysis
One of the primary outcome measures in this study is
the CMAI, a behavioural observation scale with 29
behavioural items. Each item may be scored between 1
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toms. The range on the CMAI is 29-203. In Dutch nur-
sing homes the median is 44 [44]; there is no normal
distribution, but the distribution of the change is more
or less normally distributed. The standard deviation of
difference scores (difference of 4) is 13. The expected
difference is however larger (at least 10 points). To
detect a 15% difference between the intervention (STA
OP!-protocol) and control condition with an a =. 0 5
and b = .80, 56 residents will be required. However, in
cluster randomization, a design effect should be taken
into account; clustering of items (consistency of CMAI
items [ICC] among residents in a unit is .10) and also
the effect of large differences in sample sizes per cluster
enhances the design effect [45].
In this study the design effect was estimated at 1.5; So,
1.5 × 56 = 84 residents (after 4 weeks) will be needed in
total to detect a 15% difference with an a = .05 and b =
.80. However, we expect a 50% dropout due to non-
response and loss to follow-up, i.e. we will need 168
patients in total; 84 in the intervention- and 84 in the
control group.
Intervention condition: implementation of STA OP!
A comprehensive training program for healthcare pro-
fessionals will be organized to implement the STA OP!-
protocol. Healthcare professionals participating in this
study will be nursing home physicians, psychologists,
occupational therapists and registered or certified nurses
(CNA/RN). In most of the nursing homes the majority
of the registered or certified nurses will have relatively
low educational levels 1, 2 or 3, which in Dutch is called
‘verzorgenden’ or ‘helpenden’. Nurses and physicians
who only work night shifts will be excluded from this
study. Only the CNA/RN (levels 3, 4 or 5) is authorized
to start the protocol.
Nursing home staff from all experimental units will be
trained in the stepwise working method of the STA
OP!-protocol in five meetings lasting three hours each.
The team members will be taught enhanced physical
and affective assessment skills that target needs com-
monly found in people with advanced dementia. A colla-
borating training centre, with very experienced trainers,
will provide the STA OP!-training. These trainers are
advanced practice nurses or have other medical back-
grounds and have specific professional expertise regard-
ing dementia, pain and discomfort.
In the sessions it will be discussed how nursing home
staffs can recognize symptoms related to pain and affec-
tive discomfort, and how they can communicate with
each other about these symptoms. In the first meetings
the initial two steps of the STA OP!-protocol will be
discussed, while in the follow up meetings the focus is
on the last three steps.
The steps of the STA OP!-protocol are outlined in the
following section. Each step is systematically written
down in the STA OP!-protocol, which serves as a tem-
plate for nurses and nursing home physicians to use the
Table 1 Instruments and the different assessment points
Instruments When & who? Baseline 3 months
(= ca. 12-13 weeks)
6 months
(= ca. 26 weeks)
Selection criteria - GDS (Reisberg) Pre selection NHP
- MDS-CPS Pre selection NHP
Primary Outcome - CMAI Incl. Nurse Nurse Nurse
- MDS-RAI pain scale Incl. Nurse Nurse Nurse
- NPI-NH Incl. Nurse Nurse Nurse
- PACSLAC-D Incl. Nurse & VIDEO Nurse & VIDEO Nurse
Secondary Outcome - Qualidem Incl. Nurse Nurse Nurse
- Cornell & MDS-DRS Incl. Nurse Nurse Nurse
- Medication Incl. RA RA RA
- DS-DAT Incl. VIDEO VIDEO
- FACS Incl. VIDEO VIDEO
Control variables/Demographics - (co-) Morbidity Incl. NHP
- Hospitalisation, fixation etc. Incl. RA RA RA
- Demographics; sex, age, background Incl. RA
- ADL (Katz) Incl. Nurse
- Apolipoprotein E4 Incl. RA
NHP = Nursing Home Physician, Nurse = caregiver, RA = research assistant, Incl. = included residents.
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much time it takes to decide to proceed to the subse-
quent step, depends on the specific interventions cho-
sen. However, in general when effects are lacking or
when they are limited, this should not take longer than
one week.
Other healthcare professionals can be consulted at any
time and at each step in the process.
￿ Step 0: Basic care needs
The nurse assesses whether or not basic physical care
needs are fulfilled. Basic care needs concern, for
instance hunger, thirst, a need for glasses, hearing aids
or toileting.
￿ Step 1: Physical needs assessment (nurse and nursing
home physician)
In addition to a brief physical nursing assessment, the
nurse will also fill out an observational pain instrument
(PACSLAC-D). If these assessments are negative, a nur-
sing home physician (or if available a nurse practitioner)
performs a more comprehensive physical assessment to
find other probable physical causes, such as inflamma-
tion, infection, acute illness or a chronic condition pos-
sibly responsible for the observed behaviour.
For those residents already using pain medication or
psychotropic drugs and still have behavioural symptoms
possibly related to pain or affective discomfort, the nur-
sing home physician will also assess whether the medi-
cation given is in accordance with the guidelines of the
World Health Organization (WHO) and Verenso (the
Dutch association of nursing home physicians) (also see
Step 4 and 5).
￿ Step 2: Affective needs assessment
By using a needs-oriented and tailored approach, the
nurse assesses possible problems regarding environmen-
tal stress, a possible imbalance between sensory stimu-
lating and sensory calming activities, or a lack in
meaningful human interactions. The psychologist work-
ing in the nursing home can be consulted at this step.
￿ Step 3: Non-pharmacological comfort interventions
In this step non-pharmacological comfort interventions
will be conducted and implemented, in line with the
personal history of the resident. Examples of comfort
interventions are soothing, supportive verbal communi-
cation, supportive touch, and sensory stimulation by
music, nice smells or soft materials. A study by van
Weert [46] showed that these types of comfort interven-
tions are effective in reducing discomfort in nursing
home residents.
￿ Step 4: Trial of analgesics
In this step of the protocol the nursing home physician
is advised to prescribe a trial of analgesics according to
the validated pain ladder, developed by the World
Health Organization [47]. Specific guidelines for use in
the elderly are given to each participating nursing home
physician in a training session, and similarly for physi-
cians working in control and intervention units.
￿ Step 5: Consultation of relevant other disciplines (e.g.
psychiatrist) and/or trial of prescribed psychotropic drugs
In the protocol and training sessions, nursing home
physicians are instructed to use the guidelines of the
Dutch association of nursing home physicians (Verenso)
for prescribing psychotropic medication [48]. The Ver-
enso-guidelines clearly describe how and when psycho-
tropic drugs are beneficial for dementia patients. In
general, it is believed that this medication is only indi-
cated for specific symptoms and for a fixed period of
time.
In the training session it is also discussed that in gen-
eral, a subsequent protocol step is needed when targeted
assessments are negative, or when the symptoms related
to pain or affective discomfort have not been reduced
sufficiently by the targeted interventions.
During the training, the nurses and nursing home
physicians start using the STA OP!-protocol for the resi-
dents who have been assessed by the blinded research
assistants at pre-test (in week 0) as having a CMAI,
NPI-NH and/or MDS-RAI pain scale score above the
threshold. It can be expected that the STA OP!-protocol
will also be used in other residents showing behavioural
symptoms of pain or affective discomfort (outside the
measurement weeks): this is allowed and will be regis-
tered. To promote the use of the protocol in practice, a
focus group will be formed within the units of the insti-
tution. The researcher performs site-visits ones a week
on the experimental units and provides nurses and nur-
sing home physicians feedback on their use of the STA
OP!-protocol in particular residents and answers their
questions regarding pain or affective discomfort.
Control condition
In the control condition there is also a training program
for healthcare professionals/nurses focusing on challen-
ging behaviour and pain, but without the stepwise
approach.
The nursing home physicians (and nurse practitioners
if available) in the experimental and control group
receive, besides the training sessions focusing on chal-
lenging behaviour and pain (with or without a stepwise
approach), both exactly the same training regarding the
(evidence based) treatment of pain and challenging
behaviour. The training in geriatric pain management
focuses on appropriate short- and long-acting drugs for
the treatment of acute and chronic pain, dose escalation,
analgesic escalation and management of side effects. The
training in geriatric behaviour treatment focuses on the
appropriateness of the use of psychotropic medication
for several indications and its side effects. In this addi-
tional training it is stressed that other interventions are
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experienced nursing home physician (WA).
Next to these two training programs, there is one
important change in the control condition from the
standard care situation: the nurses and nursing home
physicians are informed which residents of their units
have a CMAI, NPI-NH or MDS-RAI pain scale score
higher than threshold at pre-test (week 0), according to
the assessments of the nurses and blinded research
assistants.
Therapy compliance
In the proposed study, therapy compliance is taken into
account by the fact that the research assistant/advanced
practice nurse who visits the experimental units once a
week will have ample and structured focus on the actual
use of the protocol in practice. The site-visits will
include assessment whether the protocol is adequately
used, the patient assessments performed adequately, if
planned non-pharmacological interventions are executed
and if prescribed analgesics or psychotropic drugs are
indeed administered and used. The daily logs from the
units will provide additional information on the actual
use of the protocol, as well as reports from interdisci-
plinary meetings.
Instruments
Various baseline measurements, primary outcome mea-
sures, secondary outcome measures, demographic-, and
control variables can be distinguished in this study. The
instruments are observational instruments, which are
filled in by a contact nurse. In addition, video recordings
will be made for analysis by independent blinded obser-
vers on pain and discomfort (see Table 1).
Primary outcomes
Primary outcomes measures include symptoms of chal-
lenging behaviour and/or pain.
Challenging behaviour
Symptoms of challenging behaviour will be measured
with the Dutch version of the
Cohen-Mansfield Agitation Inventory (CMAI)
[30,31,49,50], and with the Dutch version of the Neu-
ropsychiatric Inventory-Nursing Home Version (NPI-
NH) [51-53].
The CMAI was developed to assess agitation in nur-
sing home patients [30,31]. It is more specific than gen-
eral-purpose behaviour rating scales, which usually
include self-care activities, cognition, and mood items.
The CMAI uses a 7-point scale to assess the frequency
(ranging from ‘never’ to ‘several times an hour’)o f2 9
behaviours commonly seen in nursing home residents.
Behaviours are characterized in four clusters: verbally
aggressive (e.g., directed at a person or object), verbally
nonaggressive (not directed at a specific object or per-
son), physically aggressive (directed), and physically non-
aggressive (undirected). The total score is most
commonly used to quantify behavioural disturbance.
Professional caregivers, who are usually nurses or nur-
sing assistants, assess this scale. The staffs are trained
prior to using the instrument. Factor analysis has shown
three basic dimensions underlying the 29 CMAI items:
physical aggression, physical nonaggression, and verbal
agitation. It is a reliable and valid instrument to measure
behavioural symptoms in dementia patients [49,50].
The NPI-NH is a structured interview with a health-
care professional (CNA/RN). In this interview ten
neuropsychiatric symptoms are assessed: delusions,
hallucinations, agitation/aggression, dysphoria, anxiety,
euphoria, apathy, disinhibition, irritability/lability.
Screening questions are asked to determine whether
behavioural changes are present. In the case of a posi-
tive answer, further questions are asked and the severity
and frequency of the behavioural disturbances are deter-
mined. The Dutch version of the NPI has high inter-
rater agreement and is found to be a valid rating scale
for measuring a wide range of behavioural and psycho-
logical symptoms of dementia [51,52].
Pain
Symptoms of pain will be measured with the pain scale
of the Dutch version of the Minimum Data Set of the
Resident Assessment Instrument (MDS-RAI) [34] and
with the Pain Assessment Checklist for Seniors (PAC-
SLAC-D) [37]. The MDS contains two pain items: ‘pain
frequency’ and ‘pain intensity’.I nt h eM D S ,p a i nf r e -
quency is coded as no pain (0); less than daily pain (1);
and daily pain (2) in the last 7 days. Pain intensity is
categorized as no pain; mild pain (0); moderate pain (1);
and severe pain (2, times when pain is horrible or excru-
ciating) in the last 7 days. The product of intensity and
severity in this study has to be ≥2 to be defined as clini-
cally relevant pain.
The validity and precision of pain measurement with
MDS items have been established against the Visual
Analogue Scale in a study involving 95 US nursing
home residents [34]. The definition of pain in the MDS
is ‘’Pain refers to any type of physical pain or discomfort
of the body. Pain may be localized to one area, or be
more generalized. It may be acute or chronic, continu-
ous or intermittent (comes and goes), or occur at rest
with movement. The pain experience is very subjective;
pain is whatever the resident says it is.” Coding instruc-
tions are ‘’Code for the highest level of pain present in
the last seven days” [54].
The PACSLAC-D is a brief and manageable version of
the Pain Assessment Checklist for Seniors with Limited
Ability to Communicate [35] in Dutch that was devel-
oped by Zwakhalen [37], with a three component
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of internal consistency for the complete scale (Cron-
bach’s alpha range 0.82-0.86) and for all subscales (alpha
range 0.72-0.82).
B o t ht h ep a i ns c a l eo ft h eM D S - R A Ia n dt h eP A C -
SLAC-D will be assessed by the contact nurse of a parti-
cular resident at baseline and after 3 and 6 months.
Video registrations
At baseline, 5 minute standardized video recordings of
the included patients will be made during both morning
care and mealtime. This will be repeated after three
months.
Independent, blinded raters will score the video-
recordings, by using the PACSLAC-D. These video-
recordings will also be used to independently code
another pain and discomfort scale, the Dutch version of
the Discomfort Scale- dementia of Alzheimer Type (DS-
DAT) [26,55]. The DS-DAT is an observational scale
with 9 items, and measures symptoms regarding vocali-
zations, breathing, facial expression, and body move-
ment. The reliability and validity of the Dutch version
has been established as high [55-57]. In addition, the
video-recordings will be analyzed using the Facial
Action Coding System (FACS) [58].
Secondary outcomes
Secondary outcomes include symptoms of depression,
an indication of the quality of life and changes in pre-
scriptions of medication.
Depressive symptoms
Depressive symptoms will be measured with the Cornell
depression scale and the depression rating scale of the
Minimum Data Set Depression Rating Scale (MDS-
DRS).
The MDS-DRS is a seven-item scale, with all items
scored as, 0 (indicator not exhibited), 1 (indicator of this
type exhibited at least once in the last 30 days and up
to 5 days a week) or 2 (indicator exhibited daily or
almost daily) [59]. The scores range between 0 and 14.
The mood-items in the MDS 2.0 have good inter-rater
reliability [54,60,61]. (With a cut-off point of 3, it differ-
entiates well between residents with few or many
depressive symptoms. Compared to (DSM-IV) psychia-
tric criteria for depression it has a high sensitivity (91%),
and a lower specificity (69%) [59].
The Cornell Scale is a well-known, mostly caregiver-
rated scale that is particularly suited to differentiate
between cognitive and mood symptoms, and is sensitive
to treatment effects over a wide range of depression
severity. The scale has nineteen items that are based on
the week prior to the interview and which are rated as
absent, mild or intermittent, and severe. Symptoms are
clustered into five main categories: mood related signs,
behavioural disturbance, physical signs, cyclic functions,
and ideational disturbance. Published inter-rater reliabil-
ity kappa is 0.67, internal consistency is reasonable
(0.84), and it has been found to be valid, based on com-
parison with the Hamilton Depression Rating Scale and
Research Diagnostic Criteria [38,39].
Quality of Life (QoL)
The quality of life will be measured with the Quali-
dem. The Qualidem is an easy to administer and suffi-
ciently reliable and valid rating scale that provides a
quality of life profile of persons with dementia in LTC
settings. The Qualidem can be used for evaluation as
well as for research and practice innovation. Twenty-
one of 40 items are suitable for people with very severe
dementia [40-42]. Each subscale of quality of life is
scored. It is not possible to calculate a total score of
the Qualidem. The individual item scores for each sub-
scale are summed: the higher the score, the better the
quality of life.
Demographics, baseline and control variables
Sex, age and cultural background of residents will be
derived as demographic variables from structured ques-
tionnaires filled in by nurses. A subscale of the Resi-
dents Assessment Inventor y( R A I )w i l lb eu s e dt o
obtain co-morbidity and will be filled in by the nursing
home physicians. They will also determine the stage of
dementia, measured with the Global Deterioration
Scale [29,62] and the Cognitive Performance Scale
(MDS-CPS).
The MDS-CPS is a seven-category index, ranging from
cognitively intact to very severely impaired. The scale
has shown excellent agreement with the Mini-Mental
State Examination (MMSE) in the identification of cog-
nitive impairment in research [63].
The Global Deterioration Scale (GDS) [29] consists of
a seven-point scale (1-7) ranging from ‘no global impair-
ment’ (1) to ‘very severe global impairment’ (7). Charac-
teristics of the nursing homes (such as available
disciplines, amount and nature of followed education by
health care professionals, unit sizes) will be carefully
registered and taken in to account when performing the
analyses.
Medication
Changes in prescriptions of analgesics and psychotropic
drugs (coded as defined daily dosage-DDD) will be
derived from the daily logs of contact nurses and will
also be derived from the analysis of pharmacists’ electro-
n i cp a t i e n tr e c o r d sf o rt h et o t a ls t u d yp e r i o do f
26 weeks.
Apolipoprotein Epsilon 4
The status of Apolipoprotein Epsilon 4 (Apo-E4) will be
determined as a baseline variable and will be taken from
two buccal mucosa swabs (Catch-All swabs of the firm
BIOzymTC example). The Apo-E4 protein may play a
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[64]. It is currently unclear whether the Apo-E4 protein
has an effect on non-pharmacological treatments, such
as comfort interventions. Determining the Apo-E4 is
therefore very important in intervention studies like the
present study.
Process variables
The actual use of the STA OP!-protocol will be derived
from the daily logs of contact nurses for the total study
period of 26 weeks, and from group interviews with
contact nurses and nursing home physicians in weeks
26. The researcher/research assistant making site-visits
once a week, will check the thoroughness of the log
completion by the contact nurse. After the research per-
iod the internal formed focus group will take over this
task, in order to facilitate implementation.
Patient files
The use and nature of non-pharmacological comfort
interventions, as well as the nature and number of phy-
sical restraints will be derived from daily logs by the
contact nurses and by studying patient files for the total
study period of 26 weeks.
Statistical analyses
To assess effects of the intervention on outcome vari-
ables, we will perform multilevel analyses with statistical
adjustments for differences in the relevant baseline
scores and control variables according to the intention-
to-treat principle. Where no confounding is to be
expected, univariate analysis will be applied. Both an
intention-to-treat analysis and per protocol analysis will
be performed.
Ethical approval
The study has been approved by the Medical Ethics
Review Committee of the VU University Medical Center
Amsterdam (registration number 2009/119).
Discussion
This study will evaluate the use and effectiveness of the
Dutch version of the STI-protocol. The transfer from
the American design to the Dutch design has necessi-
tated several changes due to of the different organisation
of healthcare systems. Next to the similarities between
the original STI and the Dutch version, e.g. the stepwise
approach and essentially the same content of each step,
there are some differences. For instance, the presence of
a nursing home physician and psychologist adds clinical
expertise to the team. It will be interesting to see if
these differences will influence the effects of the inter-
vention. This expertise is also available in the control
setting. This might therefore lead to smaller differences
between control and intervention then in the USA, but
it might also prove to strengthen the stepwise approach,
and show stronger effects. Furthermore, the question
arises whether the addition of a standard observational
pain scale contributes to pain assessment.
In our design are also some essential differences with
the RCT Kovach undertook. We decided to use the
CMAI and NPI-NH as behavioural outcome measures,
and PACSLAC-D and MDS-RAI pain scale as pain mea-
sures. In the STI-study, the DS-DAT was used, which is
essentially a discomfort scale. By adding measures for
depression (MDS depression rating scale and Cornell)
and quality of life (Qualidem) we believe we have the
opportunity to study more precisely the effects of this
stepwise protocol. To tackle the problem of using obser-
vational scales, which are best filled out by staff who
know the patient well, yet who might be biased because
of the intervention, we have added video recordings that
will be scored by independent raters. We will also meti-
culously register the medication used, and interventions
that are performed. By taking Buccal mucosa swabs, we
will be able to study if there are responder differences
caused by the Apo-E4 status.
A difficulty in research in nursing home care is that
the usual care of the control groups is not standardized.
Although nurses and nursing home physicians will have
some routines and standard procedures in caring for
residents with pain or affective discomfort, standard
care will differ between nursing homes. Therefore, it is
important that during the total assessment period all
prescriptions of analgesics and psychotropic drugs, and
non-pharmacological comfort interventions are carefully
registered. Another difficulty in this study is the variabil-
ity in the amount of training between the control and
intervention condition. In the control condition the
team receives a standardized training program focused
on challenging behaviour and pain, which explicitly does
not contain a stepwise approach. The intervention train-
ing is specifically designed to work with the stepwise
STA OP!-method, and this stepwise approach results in
extra training sessions. A confounder may therefore be
the extra amount of attention in the intervention group,
with a possible stronger Hawthorn effect.
In conclusion, pain and challenging behaviour are a
major problem in moderate to severe dementia patients
in nursing homes. This study aims to contribute to the
evidence-based treatment of nursing home residents
who experience discomfort, pain and behavioural
symptoms.
Acknowledgements
This project is financed by ‘Innovatiefonds Zorgverzekeraars’, the
Netherlands.
Pieper et al. BMC Geriatrics 2011, 11:12
http://www.biomedcentral.com/1471-2318/11/12
Page 9 of 11Author details
1EMGO+ Institute for Health and Care Research, van der Boechorststraat 7,
1081 BT Amsterdam, The Netherlands.
2Department of Nursing Home
Medicine, VU University Medical Center Amsterdam, van der Boechorststraat
7, 1081 BT Amsterdam, The Netherlands.
3Department of Public Health and
Primary Care, Leiden University Medical Center, Postzone V0-P, PO Box 9600,
2300 RC Leiden, The Netherlands.
4Netherlands Institute for Health Services
Research (NIVEL), PO Box 1568, 3500 BN Utrecht, The Netherlands.
5Department of Clinical Neuropsychology, VU University Amsterdam, van der
Boechorststraat 1, 1081 BT Amsterdam, The Netherlands.
6University of
Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Authors’ contributions
CK conceived and designed the original study (STI). AF and WA adjusted the
STI study into STA OP! and obtained funding. MP drafted the manuscript
and coordinates the data collection. AF, WA, ES and JS designed the STA
OP!-study and helped to draft the manuscript. All authors have been
involved in revising the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 December 2010 Accepted: 24 March 2011
Published: 24 March 2011
References
1. Gezondheidsraad: Dementie. Den Haag; 2002, publication number, 2002/004.
2. de Lange J, Poos MJJC, Schoemaker C: Hoe vaak komt dementie voor en
hoeveel mensen sterven eraan? Volksgezondheid Toekomst Verkenning,
Nationaal Kompas Volksgezondheid Bilthoven: RIVM; [http://www.
nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-aandoeningen/
psychische-stoornissen/dementie/omvang].
3. Scherder EJ, Bouma A: Is decreased use of analgesics in Alzheimer
disease due to a change in the affective component of pain? Alzheimer
Disease and Related Disorders 1997, 11:171-174.
4. Sawyer P, Lillis JP, Bodner EV, Allman RM: Substantial daily pain among
nursing home residents. J Am Med Dir Assoc 2007, 8:158-165.
5. Boerlage AA, van Dijk M, Stronks DL, de Wit R, van der Rijt CC: Pain
prevalence and characteristics in three Dutch residential homes.
European Journal of Pain 2008, 12(7):910-6.
6. Achterberg WP, Gambassi G, Finne-Soveri H, Liperoti R, Noro A, Frijters DH,
Cherubini A, Dell’aquila G, Ribbe MW: Pain in European long-term care
facilities: Cross-national study in Finland, Italy and the Netherlands. Pain
2010, 148:70-74.
7. American Geriatrics Society Panel on Chronic Pain in Older Persons: The
management of chronic pain in older persons: American Geriatrics
Society Panel on Chronic Pain in Older Persons. J Am Geriatr Soc 1998,
46:635-651.
8. Kovach CR, Noonan PE, Griffie J, Muchka S, Weissman DE: Use of the ADD
protocol. Appl Nurs Res 2001, 4(4):193-200.
9. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT: Neuropsychiatric
symptoms in nursing home patients: factor structure invariance of the
Dutch nursing home version of the neuropsychiatric inventory in
different stages of dementia. Dement Geriatr Cogn Disord 2007,
24(3):169-76.
10. Kverno K, Rabins P, Blass D, Hicks K, Black B: Prevalence and treatment of
neuropsychiatric symptoms in hospice-eligible nursing home residents
with advanced dementia. Journal of Gerontological Nursing 34(12):8-15.
11. Norton MJ, Allen RS, Snow AL, Hardin JM, Burgio LD: Predictors of need-
driven behaviors in nursing home residents with dementia and
associated certified nursing assistant burden. Aging and Mental Health
2010, 14(3):303-309.
12. Frampton M: Experience assessment and management of pain in people
with dementia. Age Ageing 2003, 32:248-51.
13. Nygaard HA, Jarland M: Are nursing home patients with dementia
diagnosis at increased risk for inadequate pain treatment? International
Journal of Geriatric Psychiatry 2005, 20(5):730-737.
14. Achterberg W, Pot AM, Scherder E, Ribbe M: Pain in the nursing home:
assessment and treatment on different types of care wards. J Pain
Symptom Manage 2007, 34(5):480-487.
15. Tait RC, Chibnall JT: Under-treatment of pain in dementia: assessment is
key. J Am Med Dir Assoc 2008, 9(6):372-4.
16. Feldt KS, Warden MA, Ryden MB: Examining pain in aggressive cognitively
impaired older adults. J of Gerontological Nursing 1998, 24(11):14-22.
17. Herr K: Chronic pain in the older patient: management strategies.
J Gerontol Nurs 2002, 28(2):28-34.
18. Horgas : Pain Management in Elderly Adults. Journal of Infusion Nursing
2003, 26(3):161-165, 2003.
19. Geda YE, Rummans TR: Pain: cause of agitation in elderly individuals with
dementia. Am J Psychiatry 1999, 156(10):1662-3.
20. Briesacher BA, Limcangco MR, Simoni-Wastila L, Doshi JA, Levens SR,
Shea DG, Stuart B: The quality of antipsychotic drug prescribing in
nursing homes. Arch Intern Med 2005, 165(11):1280-5.
21. Kovach CR, Weissman DE, Griffie J, Matson S, Muchka S: Assessment and
treatment of discomfort for people with late-stage dementia. J Pain
Symptom Manage 1999, 18(6):412-419.
22. Kovach CR, Noonan PE, Griffie J, Muchka S, Weissman DE: The assessment
of discomfort in dementia protocol. Pain Manag Nurs 2002, 3(1):16-27.
23. Kovach CR, Logan BR, Noonan PE, Schlidt AM, Smerz J, Simpson M, Wells T:
Effects of the serial trial intervention on discomfort and behavior of
nursing home residents with dementia. Am J Alzheimers Dis Other Demen
2006, 21(3):147-55.
24. Algase DL, Beck C, Kolanowski A, Whall A, Berent S, Richards K, Beattie E:
Needdriven dementia-compromised behavior: An alternative view of
disruptive behavior. American Journal of Alzheimer’s Disease 1996, 11:10-19.
25. Kovach CR, Noonan PE, Schlidt AM, Wells T: A model of consequences of
need-driven, dementia-compromised behavior. J Nurs Scholarsh 2005,
37(2):134-40, discussion 140. Review.
26. Hurley AC, Volicer BJ, Hanrahan PA, Houde S, Volicer L: Assessment of
discomfort in advanced Alzheimer patients. Res Nurs Health 1992,
15(5):369-77.
27. Ribbe MW, Ljunggren G, Steel K, Topinková E, Hawes C, Ikegami N,
Henrard JC, Jónnson PV: Nursing homes in 10 nations: a comparison
between countries and settings. Age Ageing 1997, 26(Suppl 2):3-12.
28. Conroy S, Van Der Cammen T, Schols J, Van Balen R, Peteroff P, Luxton T:
Medical services for older people in nursing homes–comparing services
in England and the Netherlands. J Nutr Health Aging 2009, 13(6):559-63.
29. Reisberg B, Ferris S, de Leon MJ, Crook T: The Global Deterioration Scale
(GDS) for assessment of primary degenerative dementia. Am J Psychiatry
1982, 139:1136-1139.
30. Cohen-Mansfield J, Marx MS, Rosenthal AS: A description of agitation in
the nursing home. J Gerontol 1989, 44:77-84.
31. de Jonghe JFM, Kat MG: Factor structure and validity of the Dutch
version of the Cohen-Mansfield Agitation Inventory (CMAI-D). Journal of
the American Geriatrics Society 1996, 44(7):888-889.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA,
Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment
of psychopathology in dementia. Neurology 1994, 44(12):2308-14.
33. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology
in dementia patients. Neurology 1997, 48(suppl 6):S10-S16.
34. Fries BE, Simon SE, Morris JN, Flodstrom C, Bookstein FL: Pain in U.S.
Nursing Homes: Validating a Pain Scale for the Minimum Data Set. The
Gerontologist 2001, 41(2):173-179.
35. Fuchs-Lacelle S, Hadjistavropoulos T: Development and preliminary
validation of the pain assessment checklist for seniors with limited
ability to communicate (PACSLAC). Pain Manag Nurs 2004, 5:37-49.
36. Zwakhalen SM, Hamers JP, Abu-Saad HH, Berger MP: Pain in elderly people
with severe dementia: a systematic review of behavioural pain
assessment tools. BMC Geriatr 2006, 6:3.
37. Zwakhalen SMG, Hamers JPH, Berger MPF: Improving the clinical
usefulness of a behavioural pain scale for older people with dementia.
Journal of Advanced Nursing 2007, 58(5):493-502.
38. Conn D, Thorpe L: Assessment of behavioural and psychological
symptoms associated with dementia. Can J Neurol Sci 2007, 34(Suppl 1):
S67-71.
39. Dröes RM: Cornell Scale for Depression in Dementia. Nederlandse
vertaling. Vakgroep Psychiatrie, Vrije Universiteit, Amsterdam; 1993.
40. Ettema TP, Dröes RM, de Lange J, Mellenbergh GJ, Ribbe MW: QUALIDEM:
development and evaluation of a dementia specific quality of life
instrument. Scalability, reliability and internal structure. Int J Geriatr
Psychiatry 2007, 22(6):549-56.
Pieper et al. BMC Geriatrics 2011, 11:12
http://www.biomedcentral.com/1471-2318/11/12
Page 10 of 1141. Ettema TP, Dröes RM, de Lange J, Mellenbergh GJ, Ribbe MW: QUALIDEM:
development and evaluation of a dementia specific quality of life
instrument–validation. Int J Geriatr Psychiatry 2007, 22(5):424-30.
42. Schölzel-Dorenbos CJ, Ettema TP, Bos J, Boelens-van der Knoop E,
Gerritsen DL, Hoogeveen F, de Lange J, Meihuizen L, Dröes RM: Evaluating
the outcome of interventions on quality of life in dementia: selection of
the appropriate scale. Int J Geriatr Psychiatry 2007, 22(6):511-9.
43. Katz S, Down TD, Cash HR, et al: Progress in the Development of the
Index of ADL. Gerontologist 1970, 10:20-30.
44. Zuidema SU, Derksen E, Verhey FR, Koopmans RT: Prevalence of
neuropsychiatric symptoms in a large sample of Dutch nursing home
patients with dementia. Int J Geriatr Psychiatry 2007, 22(7):632-8.
45. Eldridge SM, Ashby D, Kerry S: Sample size for cluster randomized trials:
effect of coefficient of variation of cluster size and analysis method. Int J
epidem 2006, 35:1292-1300.
46. van Weert JC, van Dulmen AM, Spreeuwenberg PM, Ribbe MW, Bensing JM:
Behavioral and mood effects of snoezelen integrated into 24-hour
dementia care. J Am Geriatr Soc 2005, 53(1):24-33.
47. World Health Organization Pain Ladder: [http://www.who.int/cancer/
palliative/painladder].
48. Ypma-Bakker MEM, Glas ER, Hagens JHAM, et al: NVVA-richtlijn
Probleemgedrag. Tijdschrift Verpleeghuisgeneeskunde. 2002, 26:5-31,
revised december 2008: Smalbrugge M etal. 2008.
49. Finkel S, Lyons JS, Anderson RL: Reliability and validity of the Cohen-
Mansfield Agitation Inventory in institutionalized elderly. Int J Geriatr
Psychiatry 1992, 7:487-90.
50. Koss E, Weiner M, Ernesto C, Cohen-Mansfield J, Ferris SH, Grundman M,
Schafer K, Sano M, Thal LJ, Thomas R, Whitehouse PJ: Assessing patterns of
agitation in Alzheimer’s disease patients with the Cohen-Mansfield
Agitation Inventory. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis
Assoc Disord 1997, 11(Suppl 2):S45-50.
51. Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT,
Schnelle JF: The use of the Neuropsychiatric Inventory in nursing home
residents: Characterization and measurement. American Journal of
Geriatric Psychiatry 2000, 8:75-83.
52. Kat MG, de Jonghe JFM, Aalten P, Kalisvaart CJ, Droes RM, Verhey FRJ:
Neuropsychiatric symptoms of dementia: psychometric aspects of the
Dutch Neuropsychiatric Inventory (NPI). Tijdschr Gerontol Geriatr 2002,
33:150-155.
53. Koopmans RT, van der Molen M, Raats M, Ettema TP: Neuropsychiatric
symptoms and quality of life in patients in the final phase of dementia.
Int J Geriatr Psychiatry 2009, 24(1):25-32.
54. Morris JN, Murphy K, Nonemaker S: Long term care facility Resident
AssessmentInstrument (RAI) user’s manual version 2.0. Baltimore: HCFA;
1995.
55. van der Steen JT, Ooms ME, van der Wal G, Ribbe MW: Het meten van
(on)welbevinden bij demente patiënten. Tijdschr Gerontol Geriatr 2002,
33(6):257-63.
56. Hoogendoorn LI, Kamp S, Mahomed CA, Adèr HJ, Ooms ME, van der
Steen JT: De rol van de observator in de betrouwbaarheid van de
Nederlandse versie van de Discomfort Scale-Dementia of Alzheimer
Type (DS-DAT). Tijdschr Gerontol Geriatr 2001, 32(3):117-21.
57. Van der Steen JT, Adèr HJ, van Assendelft JH, Kooistra M, Passier PE,
Ooms ME: Retrospectieve afname van de Nederlandse versie van de
Discomfort Scale–Dementia of Alzheimer type (DS-DAT): is inschatten
achteraf voldoende valide en betrouwbaar? Tijdschr Gerontol Geriatr 2003,
34(6):254-9.
58. Kunz M, Scharmann S, Hemmeter U, Schepelmann K, Lautenbacher S: The
facial expression of pain in patients with dementia. Pain 2007, 133(1-
3):221-8.
59. Burrows AB, Morris JN, Simon SE, Hirdes JP, Phillips C: Development of a
minimum data set-based depression rating scale for use in nursing
homes. Age Ageing 2000, 29(2):165-72.
60. Morris JN, Hawes C, Fries BE: Designing the National Resident Assessment
Instrument for Nursing Homes. The Gerontologist 1990, 30:293-307.
61. Morris JN, Nonemaker S, Murphy K, Hawes C, Fries BE, Mor V, Phillips C: A
commitment to change: revision of HCFA’s RAI. J Am Geriatr Soc 1997,
45(8):1011-6.
62. Reisberg B, Ferris SH, Franssen E: An ordinal functional assessment tool
for Alzheimer’s-type dementia. Hospital and Community Psychiatry 1985,
36:593-595.
63. Hartmaier SL, Sloane PD, Guess HA, Koch GG, Mitchell CM, Phillips CD:
Validation of the Minimum Data Set Cognitive Performance scale:
agreement with the mini-mental state examination. J Gerontol Med Sci
1995, 50:M128-33.
64. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M,
Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J,
Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M:
Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple
ascending dose trial of bapineuzumab in mild to moderate Alzheimer
disease. Neurology 2009, 73(24):2061-70.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2318/11/12/prepub
doi:10.1186/1471-2318-11-12
Cite this article as: Pieper et al.: The implementation of the serial trial
intervention for pain and challenging behaviour in advanced dementia
patients (STA OP!): a clustered randomized controlled trial. BMC
Geriatrics 2011 11:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pieper et al. BMC Geriatrics 2011, 11:12
http://www.biomedcentral.com/1471-2318/11/12
Page 11 of 11